Journal
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
Volume 85, Issue 4, Pages 739-747Publisher
AMER SOC TROP MED & HYGIENE
DOI: 10.4269/ajtmh.2011.10-0496
Keywords
-
Funding
- National Institute of Allergy and Infectious Diseases (NIAID/NIH) [N01-AI-40085]
- Oswald Cruz Foundation [PDTIS-RVR9]
- National Science Foundation [CCF-0845407]
- Brazilian National Research Council (CAPES)
- Direct For Computer & Info Scie & Enginr
- Division of Computing and Communication Foundations [845407] Funding Source: National Science Foundation
Ask authors/readers for more resources
From September 2005 to March 2007, 238 individuals being vaccinated for the first time with the yellow fever (YF) -17DD vaccine were enrolled in a cohort established in Recife, Brazil. A prospective study indicated that, after immunization, anti-YF immunoglobulin M (IgM) and anti-YF IgG were present in 70.6% (IgM) and 98.3% (IgG) of the vaccinated subjects. All vaccinees developed protective immunity, which was detected by the plaque reduction neutralization test (PRNT) with a geometric mean titer of 892. Of the 238 individuals, 86.6% had IgG antibodies to dengue virus; however, the presence of anti-dengue IgG did not interfere significantly with the development of anti-YF neutralizing antibodies. In a separate retrospective study of individuals immunized with the 17DD vaccine, the PRNT values at 5 and 10 years post-vaccination remained positive but showed a significant decrease in neutralization titer (25% with PRNT titers < 100 after 5 years and 35% after 10 years).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available